TABLE OF CONTENTS

1. INTRODUCTION 25
1.1. OBJECTIVES OF THE STUDY 25
1.2. MARKET DEFINITION 25
1.3. OVERVIEW OF GLOBAL BREAST LESION LOCALIZATION MARKET 25
1.4. CURRENCY AND PRICING 26
1.5. LIMITATION 26
1.6. MARKETS COVERED 27
2. MARKET SEGMENTATION 29
2.1. MARKETS COVERED 29
2.2. GEOGRAPHIC SCOPE 30
2.3. YEARS CONSIDERED FOR THE STUDY 31
2.4. CURRENCY AND PRICING 31
2.5. RESEARCH METHODOLOGY 32
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35
2.7. SECONDARY SOURCES 36
2.8. ASSUMPTIONS 36
3. EXECUTIVE SUMMARY 37
4. MARKET OVERVIEW 40
4.1. DRIVERS 42
4.1.1. TECHNOLOGICAL ADVANCEMENTS IN BREAST LOCALIZATION 42
4.1.2. RISING PREVALENCE OF BREAST CANCERAND INCREASING BREAST CANCER SURGERIES 42
4.1.3. INCREASING NUMBER OF GOVERNMENT AND NON-GOVERNMENT REIMBURSEMENT POLICIES 43
4.1.4. INCREASING AWARENESS AMONG PEOPLE FOR THE DIAGNOSIS OF BREAST CANCER 44
4.1.5. INNOVATIONS OF NEW TECHNOLOGIES AND METHODS FOR BREAST CANCER LESION LOCALIZATION 44
4.2. RESTRAINTS 45
4.2.1. REGULATORY SCENARIOS IN BREAST LOCALIZATION 45
4.2.2. PRODUCT RECALL 45
4.3. OPPORTUNITIES 46
4.3.1. EMERGING MARKET 46
4.3.2. RISING MEDICAL TOURISM 46
4.4. CHALLENGES 46
4.4.1. RISK ASSOCIATED WITH THE BREAST SURGERY AND PAINFUL CONSEQUENCES 46
5. PREMIUM INSIGHTS 47
6. GLOBAL BREAST LESION LOCALIZATION METHODS MARKET, BY TYPE 50
6.1. OVERVIEW 51
6.2. WIRE LOCALIZATION 53
6.3. RADIOISOTOPE LOCALIZATION 54
6.3.1. RADIOACTIVE SEED LOCALIZATION 55
6.3.2. RADIO OCCULT LESION LOCALIZATION 55
6.4. MEGNATIC TRACERS 56
6.5. OTHERS 57
7. GLOBAL BREAST LESION LOCALIZATION METHODS MARKET,
BY BIOPSY TECHNIQUE 58
7.1. OVERVIEW 59
7.2. FINE NEEDLE ASPIRATION BIOPSY 61
7.3. VACUUM ASSISTED CORE BIOPSY 62
7.4. CORE NEEDLE BIOPSY 63
7.5. SURGICAL BIOPSY 64
7.5.1. EXCISIONAL BIOPSY 65
7.5.2. INCISIONAL BIOPSY 65
8. GLOBAL BREAST LESION LOCALIZATION METHODS MARKET,
BY END USER 66
8.1. OVERVIEW 67
8.2. HOSPITALS 69
8.3. ONCOLOGY CLINICS 70
8.4. DIAGNOSTIC CENTERS 71
8.5. AMBULATORY SURGICAL CENTERS 72
9. GLOBAL BREAST LESION LOCALIZATION METHODS MARKET,
BY GEOGRAPHY 73
9.1. OVERVIEW 74
9.2. NORTH AMERICA 81
9.2.1. U.S. 90
9.2.2. CANADA 93
9.2.3. MEXICO 96
9.3. EUROPE 99
9.3.1. GERMANY 109
9.3.2. FRANCE 112
9.3.3. U.K. 115
9.3.4. ITALY 118
9.3.5. SPAIN 121
9.3.6. RUSSIA 124
9.3.7. SWITZERLAND 127
9.3.8. NETHERLANDS 130
9.3.9. TURKEY 133
9.3.10. BELGIUM 136
9.3.11. REST OF EUROPE 139
?
9.4. ASIA PACIFIC 140
9.4.1. JAPAN 150
9.4.2. CHINA 153
9.4.3. INDIA 156
9.4.4. SOUTH KOREA 159
9.4.5. AUSTRALIA 162
9.4.6. THAILAND 165
9.4.7. SINGAPORE 168
9.4.8. MALAYSIA 171
9.4.9. INDONESIA 174
9.4.10. PHILIPPINES 177
9.4.11. REST OF Asia-Pacific 180
9.5. SOUTH AMERICA 181
9.5.1. BRAZIL 190
9.5.2. REST OF THE SOUTH AMERICA 193
9.6. MIDDLE EAST & AFRICA 194
9.6.1. SOUTH AFRICA 203
9.6.2. REST OF THE MIDDLE EAST & AFRICA 206
10. GLOBAL BREAST LESION LOCALIZATION METHODS MARKET,
COMPANY LANDSCAPE 207
10.1. COMPANY SHARE ANALYSIS; GLOBAL 207
10.2. COMPANY SHARE ANALYSIS; NORTH AMERICA 208
10.3. COMPANY SHARE ANALYSIS; EUROPE 209
10.4. COMPANY SHARE ANALYSIS; ASIA-PACIFIC 210
?
11. COMPANY PROFILES 211
11.1. C. R. BARD, INC. 211
11.1.1. COMPANY OVERVIEW 211
11.1.2. C.R. BARD; REVENUE ANALYSIS 212
11.1.3. PRODUCT PORTFOLIO 213
11.1.4. RECENT DEVELOPMENTS 213
11.2. CP MEDICAL, INC. 214
11.2.1. COMPANY OVERVIEW 214
11.2.2. CP MEDICAL, INC.;COMPANY SNAPSHOT 214
11.2.3. PRODUCT PORTFOLIO 215
11.2.4. RECENT DEVELOPMENTS 215
11.3. CIANNA MEDICAL 216
11.3.1. COMPANY OVERVIEW 216
11.3.2. CIANNA MEDICAL; REVENUE ANALYSIS 216
11.3.3. PRODUCT PORTFOLIO 216
11.3.4. RECENT DEVELOPMENTS 217
11.4. COOK GROUP 218
11.4.1. COMPANY OVERVIEW 218
11.4.2. COOK GROUP; COMPANY SNAPSHOT 218
11.4.3. PRODUCT PORTFOLIO 218
11.4.4. RECENT DEVELOPMENTS 218
11.5. STERYLAB S.R.L. 219
11.5.1. COMPANY OVERVIEW 219
11.5.2. STERYLAB S.R.L.;COMPANY SNAPSHOT 219
11.5.3. PRODUCT PORTFOLIO 220
11.5.4. RECENT DEVELOPMENTS 220
?
11.6. SOMATEX MEDICAL TECHNOLOGIES GMBH 221
11.6.1. COMPANY OVERVIEW 221
11.6.2. SOMATEX MEDICAL TECHNOLOGIES GMBH; COMPANY SNAPSHOT 221
11.6.3. PRODUCT PORTFOLIO 222
11.6.4. RECENT DEVELOPMENTS 222
11.7. ELUCENT MEDICAL. 223
11.7.1. COMPANY OVERVIEW 223
11.7.2. ELUCENT MEDICAL ;COMPANY SNAPSHOT 223
11.7.3. PRODUCT PORTFOLIO 223
11.7.4. RECENT DEVELOPMENTS 223
11.8. ARGON MEDICAL 224
11.8.1. COMPANY OVERVIEW 224
11.8.2. ARGON MEDICAL; COMPANY SNAPSHOT 224
11.8.3. PRODUCT PORTFOLIO 225
11.8.4. RECENT DEVELOPMENTS 225
11.9. TSUNAMI S.R.L. 226
11.9.1. COMPANY OVERVIEW 226
11.9.2. TSUNAMI S.R.L.; COMPANY SNAPSHOT 226
11.9.3. PRODUCT PORTFOLIO 226
11.9.4. RECENT DEVELOPMENTS 226
11.10. M.D.L. SRL 227
11.10.1. COMPANY OVERVIEW 227
11.10.2. M.D.L. SRL; COMPANY SNAPSHOT 227
11.10.3. PRODUCT PORTFOLIO 227
11.10.4. RECENT DEVELOPMENTS 227
?
11.11. BIOMEDICAL SRL 228
11.11.1. COMPANY OVERVIEW 228
11.11.2. BIOMEDICAL SRL; COMPANY SNAPSHOT 228
11.11.3. PRODUCT PORTFOLIO 228
11.11.4. RECENT DEVELOPMENTS 228
12. RELATED REPORTS 229

?